Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

GLP-1 drugs such as Ozempic and Mounjaro have been heralded as some of the most important drug breakthroughs ever.

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The following is a summary of “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis,” published in the November ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have ...

About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...